Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-30
2005-08-30
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S300000, C544S333000, C546S121000
Reexamination Certificate
active
06936617
ABSTRACT:
This invention relates to heteroaryl substituted fused bicyclic heteroaryl compounds, such as heteroaryl substituted imidazopyridines, imidazopyrazines, imidazopyridizines, imidazopyrimidines, and imidazothiazoles, which may be described by Formula I or Formula II:The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAAreceptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Processes for preparing compounds of Formula I and Formula II are disclosed.This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I or Formula II in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAAreceptors in tissue sections.
REFERENCES:
patent: 6271241 (2001-08-01), DeSimone et al.
patent: 6358949 (2002-03-01), DeSimone et al.
patent: 6380210 (2002-04-01), DeSimone et al.
patent: 6420365 (2002-07-01), Peterson et al.
patent: WO 96/34866 (1996-11-01), None
patent: WO 99/37303 (1999-07-01), None
patent: WO 99/47131 (1999-09-01), None
patent: WO 99/47142 (1999-09-01), None
patent: WO 99/47171 (1999-09-01), None
patent: WO 02/050062 (2001-12-01), None
Cooper et al., The Biochemical Basis of Neuropharmacology 6th ed., (1991), pp. 145-148.
Da-Rocha, et al., J. Psychopharmacology (1997) 11(3) 211-218.
Jones, Jr. et al., J. Het. Chem. (1987), p. 1221.
Huff, et al., JCS Perkin 'Trans. I (1972), p. 2584.
Lee, et al., Alcohol and Alcoholism (1996) 31 Suppl. 27-32.
Mohler et al., Neuroch. Res. (1995) 20(5), pp. 631-636.
Oravcova et al., Journal of Chromatograph B (1996) vol. 677, pp. 1-27.
Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Co., Easton PA, p. 1418 (1985).
Smith, et al., Am. J. Psychiatry (1998) 155(10) pp. 1339-1345.
Tang, C. C., et al., J. Am. Chem. Soc. (1978), 100, 3918.
Thomas and Tallman J. Bio. Chem. (1981) 156: pp. 9838-9842.
Thomas and Tallman, J. Neurosci. (1983) 3:pp. 433-440.
White and Gurley, NeuroReport (1995) 6: pp. 1313-1316.
White, et al., Receptors and Channels (1995) 3: pp. 1-5.
Albaugh Pamela
Ghosh Manuka
Hutchison Alan
Li Guiying
Liu Nian
McDonnell Boehnen & Hulbert & Berghoff LLP
Neurogen Corporation
LandOfFree
Heteroaryl substituted fused bicyclic heteroaryl compound as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl substituted fused bicyclic heteroaryl compound as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl substituted fused bicyclic heteroaryl compound as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3457382